Physician profile
Ruth Pan
NPI 1548596828
$831.61
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.08 · 2020: $334 · 2021: $363 · 2022: $34.74.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $377.64 | 2019-2022 | |
| Glaxosmithkline, LLC. | $154.34 | 2019-2021 | |
| Lilly USA, LLC | $94.49 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $83.52 | 2019-2021 | |
| Abbvie INC. | $47.50 | 2020-2021 | |
| Boston Scientific Corporation | $25.33 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.67 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $24.12 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Pan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.